相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AACE Comprehensive Diabetes Management Algorithm 2013
Alan Garber et al.
Endocrine Practice (2015)
Metformin plus saxagliptin for type 2 diabetes
Andre J. Scheen
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
A. Maida et al.
DIABETOLOGIA (2011)
New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
Y. M. Cho et al.
DIABETOLOGIA (2011)
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
Giuseppe Derosa et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2011)
Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
E. M. Migoya et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
T. Forst et al.
DIABETIC MEDICINE (2010)
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
B. Goke et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
Debora Williams-Herman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
M. Jadzinsky et al.
DIABETES OBESITY & METABOLISM (2009)
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
E. Bosi et al.
DIABETES OBESITY & METABOLISM (2009)
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Richard E. Pratley
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
M. A. Nauck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
Itamar Raz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
R. Scott et al.
DIABETES OBESITY & METABOLISM (2008)
Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice
Yusuke Moritoh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Novel combination treatment of type 2 diabetes DPP-4 inhibition
Bo Ahren
VASCULAR HEALTH AND RISK MANAGEMENT (2008)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Metformin - New understandings, new uses
RS Hundal et al.
DRUGS (2003)
分享论文
